Robert Gardner Harrison Sells 2,264 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 2,264 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $6.47, for a total transaction of $14,648.08. Following the sale, the insider now directly owns 114,573 shares of the company’s stock, valued at $741,287.31. The trade was a 1.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Friday, January 10th, Robert Gardner Harrison sold 14,209 shares of Sera Prognostics stock. The shares were sold at an average price of $7.39, for a total transaction of $105,004.51.

Sera Prognostics Stock Up 0.6 %

SERA traded up $0.04 during trading on Tuesday, hitting $6.37. The company’s stock had a trading volume of 134,610 shares, compared to its average volume of 143,614. The business’s 50 day simple moving average is $7.44 and its 200-day simple moving average is $7.31. The firm has a market cap of $215.13 million, a PE ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Equities research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in Sera Prognostics by 321.6% in the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after buying an additional 30,093 shares during the period. Bank of New York Mellon Corp increased its stake in Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after acquiring an additional 75,441 shares during the last quarter. Geode Capital Management LLC increased its position in Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares during the last quarter. Finally, State Street Corp raised its position in Sera Prognostics by 8.8% during the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after purchasing an additional 34,479 shares during the period. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.